Bank Upgrades Invitrogen Stock on Anticipated 'Benefit' From R&D Spend | GenomeWeb
NEW YORK (GenomeWeb News) - An investment banks today upgraded Invitrogen’s stock despite missed second-quarter estimates and revised forecasts.
 
An analyst at Banc of America Securities upgraded the shares to “Buy” from “Neutral” and said the company “will begin to benefit” from the two-year investment in research and development and facility expansions.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.